Latest Breaking News On - University hospital of nantes - Page 5 : comparemela.com

Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hyperc

TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study:Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months.

United statesFrance generalEuropean regional development fundUniversity hospital of nantesResearch developmentYoung innovative companyIndustrial affairsPublic affairsEuropean unionAmerican heart association annual meetingInnovative companyAmerican heart association annualRegulatory newsUniversity hospitalInstitut de cancAmerican heart association

The International Myeloma Foundation (IMF) Honors 2022 Research Achievement Awardees, Dr Hervé Avet-Loiseau and Dr Bruno Paiva

/PRNewswire/ The International Myeloma Foundation (IMF) is proud to announce the recipients of this year s Robert A. Kyle Achievement Award and Brian G.M..

United statesBruxelles capitaleRoberta kyleYelak biruRoberta kyle mayoBriangm durieHead of the hematology laboratoryInternational myeloma working groupSwan research initiativeAmerican society of clinical oncologyUniversity hospital of nantesDrug administrationResearch developmentMonoclonal gammopathies research laboratoryUniversity hospital centerUniversity of brussels

OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaDominique costantiniAsahi kaseiMark hensleyNantes university hospitalUniversity hospital of nantesBoehringer ingelheimVeloxis pharmaceuticals incAsahi kasei groupCaroline barnhilloak state communicationsCompany partner in transplantationAsahi kaseithe kasei groupMedia contact veloxis pharmaceuticals incVeloxis pharmaceuticalsUniversity hospital

Sanofi s Sarclisa combination shows positive results in multiple myeloma patients

Sarclisa is a monoclonal antibody which targets a specific epitope on the CD38 receptor on multiple myeloma cells - News - PharmaTimes

Philippe moreauPeter adamsonUniversity hospital of nantesEuropean society for medical oncologyControversies in multiple myeloma world congressMultiple myeloma world congressEuropean societyUniversity hospital

Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy

Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival (mPFS) of 35.7 months (Hazard Ratio [HR] 0.58; 95% Confidence Interval [CI]: 25.8 to 44.0; n=179), compared to 19.2 months in .

France generalKd sarclisaPeterc adamsonPhilippe moreauUniversity hospital of nantesEuropean unionDrug administrationHead of the department hematologyGlobal head of oncology clinical developmentControversies in multiple myeloma world congressEuropean society for medical oncology onHazard ratioConfidence intervalIndependent reviewMultiple myeloma world congressEuropean society